Medtronic has promoted their General Manager of enabling technologies, cranial, and spinal technologies business, Ms. Linnea Burman, to SVP and President of the neurovascular business. Medtronic’s Neurovascular business focuses on stroke treatment.
Ms. Burman’s new responsibilities entail the portfolio strategy, product development, commercial execution, and financial performance of the unit. Ms. Burman will report to Brett Wall, President of the Neuroscience Portfolio. In her previous role as General Manager of enabling technologies, cranial, and spinal technologies business, Ms. Burman led commercial growth strategies and drove a culture of collaboration too.
The Neuroscience Portfolio is the second largest in Medtronic’s range of portfolios and is rated right after the cardiovascular segment. This segment encompasses three divisions, namely cranial and spinal technologies, specialty therapies, and neuromodulation.
“I look forward to working with my new team to build on our proven track record of advancing stroke care practices, fostering new partnerships within the neurovascular community, and developing effective therapies grounded in compelling clinical evidence,” Burman said.
Burman is set to replace Dan Volz, who is now the Senior Vice President of global commercial transformation.